Income Statement Presentation 2023

Ophthalmology: Adding new indications Positive Ph III results to be presented at Angiogenesis VABYSMO Vabsymo in RVO Ph III (BALATON/COMINO) susvim o™ Susvimo in DME ranibizumab injection susvimo™ ranibizumab injection Ph III (PAGODA) Week Day 1 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 Arm A Faricimab 6.0 mg 6x WEEK Q4W followed by PTI Arm B Aflibercept 2.0 mg 6x Q4W followed by faricimab PTI PDS implantation and initial fill Primary Endpoint D1 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 104 112 Roche Susvimo in DR Ph III (PAVILION) Primary Endpoint IR virtual event February 13th MIAMI 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 841 88 Angiogenesis Feb 10-11 100 112 X Y Z Final C ○ WEEK D1 4 8 12 Final C Arm A: PDS Q36W, N = 106 ○ ○ OOOOOO Arm A: PDS Q24W, n=381 PDS extension phase Arm B: Monthly ranibizumab, n=253 Primary endpoint at week 24 Core study end at week 72 PDS implantation and initial filla Fixed treatment interval Faricimab PTI Faricimab 6.0 mg Faricimab 6.0 mg PTI/sham Aflibercept 2.0 mg Final study visit O Intravitreal ranibizumab 0.5 mg loading dose Intravitreal ranibizumab 0.5 mg ☐ PDS implantation and initial fill POS refill-exchange ° Patients assessed for supplemental treatment O Visit with no refill-exchange or intravitreal ranibizumab 00 O O O Refill-exchange interval 36 weeks post-implantation Arm B: Control (observation³), N = 68 O O O PDS extension phase Intravitreal ranibizumab 0.5 mg PDS refill-exchange PDS implantation and initial fillb ○ Visit with no refill-exchange or intravitreal ranibizumab Primary endpoint Change from baseline in BCVA at week 24 Primary endpoint BCVA score change from baseline averaged over weeks 60 and 64 as measured via ETDRS chart Primary endpoint Percentage of patients with a ≥2- step improvement from baseline on the ETDRS-DRSS at week 52 • All studies met their respective primary endpoints; safety profiles were consistent with previous trials • Results to be presented at the Angiogenesis virtual medical meeting (Feb 10-11) • IR virtual event planned for Feb 13th (4:30-5:30pm CET/7:30 - 8:30am PST); clinical results to be presented by Veeral Sheth, MD (retinal specialist and clinical investigator) (B/C)RVO=(branch/central) retinal vein occlusion; BCVA-best-corrected visual acuity; HRVO=hemiretinal vein occlusion; CST=central subfield thickness; PTI=personalized treatment interval; QXW-every X weeks; PDS=port delivery system; DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration; DR-diabetic retinopathy; EDTRS(-DRSS)-early treatment diabetic retinopathy study (-diabetic retinopathy severity scale); Eylea (aflibercept) is a registered trademark/product of Regeneron 34 4

View entire presentation